Avicenna Alliance: enhanced knowledge, improved decisions, better outcomes
FULL MENU

Avicenna Alliance Task Forces

To effectively address critical questions related to the adoption and deployment of in silico methods for specific topics, the Avicenna Alliance has established dedicated Task Forces, composed of experts from various fields, ensuring a multidisciplinary approach to solving complex issues.

These groups collaborate to achieve concrete progress for matters as diverse as In silico AI, Patient involvement, Horizon Europe Projects, Pharmaceutical strategy, In silico oncology, Notified Bodies and Standard Organizations, etc.

By leveraging diverse expertise and fostering strong industry-academia relationships – each Task Force is led by 2 co-chairs one from academia and one from industry - the Task Forces aim to pave the way for widespread implementation and acceptance of in silico practices, ultimately benefiting patients and advancing scientific progress.


APAC Task Force International Affairs Working Group APAC Task Force Mission: Nurture a community of collaboration among Regulators, Industry, and Academia in the APAC region to advance in silico methods, best practices, and policies for Regulatory Science and Innovation Artificial intelligence (AI) Task Force Research & Technology Working Group Artificial intelligence (AI) Task Force Mission: Engage in all AA activities related to AI Cancer & In Silico Oncology Task Force Research & Technology Working Group Cancer & In Silico Oncology Task Force Mission: Accelerate, optimize and personalize cancer treatment through the development, clinical validation and clinical translation of in silico methods Clinical Deployment Task Force In Silico Application Working Group Clinical Deployment Task Force Mission: Promote use of in silico medicine from product development to clinical practice CMC Application Task Force In Silico Application Working Group CMC Application Task Force Mission: Promote use of in silico solutions in CMC throughout product lifecycle EMA Collaboration Task Force Policy Development Working Group EMA Collaboration Task Force Mission: Closely collaborate with the European Medicine Agency (EMA) to inform them about the progress of in silico methods and learn about EMA requirements to accept digital evidence Global Harmonization Task Force International Affairs Working Group Global Harmonization Task Force Mission: Inform and educate regulatory agencies around the world to ensure harmonized adoption of in silico methods Good Simulation Practice (GSP) Task Force Policy Development Working Group Good Simulation Practice (GSP) Task Force Mission: Drafting a Good Simulation Practice document widely recognized and accepted similar to the Good Clinical Practice Horizon Europe Task Force Research & Technology Working Group Horizon Europe Task Force Mission: Monitor, influence & inform on Horizon Europe Funding In Silico Liabilities Task Force In Silico Application Working Group In Silico Liabilities Task Force Mission: Investigate and document the liabilities and responsibilities for software and modeler developer of in silico solutions Nonclinical Application Task Force In Silico Application Working Group Nonclinical Application Task Force Mission: Promote use of in silico solutions to conduct smarter (3R’s) nonclinical studies Notified Bodies (NB) Task Force Policy Development Working Group Notified Bodies (NB) Task Force Mission: Systematic engagement with NBs to advance in silico trials in Europe Pharmaceutical Strategy (Pharma) Task Force Policy Development Working Group Pharmaceutical Strategy (Pharma) Task Force Mission: Accelerate Adoption by Healthcare Stakeholders of In Silico Medicine for Bringing New Medicine to Patients Public & Patient Involvement (PPI) Task Force Policy Development Working Group Public & Patient Involvement (PPI) Task Force Mission: Empower the public & patients to understand the potential of in silico medicine, improve healthcare creating ‘user demand’, encourage greater funding and drive broader clinical and regulatory adoption for enhanced impact Tissue Characterization Task Force Research & Technology Working Group Tissue Characterization Task Force Mission: Create a data base of biological tissue properties with Certificate of Birth UK In Silico Regulatory Innovation Task Force International Affairs Working Group UK In Silico Regulatory Innovation Task Force Mission: Nurture a cross-sector UK in silico trials community for regulatory science & innovation to produce evidence and harmonize standards in the UK accelerating in silico adoption in regulations

NEWS

News Virtual launch of

Virtual launch of "Toward Good Simulation Practice" book

On May 8, 2024, the virtual launch of "Toward Good Simulation Practice: Best Practices for the Use of Computational Modeling and Simulation (CM&S) in the Regulatory Process of Biomedical Products" took place, marking a significant milestone in regulatory science and industry.

News Appointment of Avicenna Formal Administrators

Appointment of Avicenna Formal Administrators

At its recent General Assembly, the members of the Avicenna Alliance have confirmed that three members of the Avicenna Board will act as legal representatives of the Avicenna Alliance. As a Belgian non-profit organisation, the Avicenna Alliance allocate the following positions:

News Avicenna at FDA / MDIC Event in Washington, April 16 - 17

Avicenna at FDA / MDIC Event in Washington, April 16 - 17

Many representatives of the Avicenna Alliance networked with good friends and in silico thought leaders from around the world at the FDA / MDIC symposium on Computation Modeling & Simulation in Washington.

Sign up for our monthly newsletter!

Sign up for our monthly newsletter!

Fill in the fields you find below

Avicenna Alliance is an initiative of:

Avicenna VPH

© 2018-2024 Avicenna Alliance | powered by We Berry